Publication | Open Access
PD‐1 inhibitors for non‐small cell lung cancer patients with special issues: Real‐world evidence
48
Citations
23
References
2020
Year
Given the relatively low incidence of immune-related AEs and the comparability of clinical outcomes, ICIs can be treatment option of NSCLC patients with special issues.
| Year | Citations | |
|---|---|---|
Page 1
Page 1